C-Met targeting polypeptide and application thereof

Abstract

The invention discloses a C-Met targeting polypeptide and application thereof in tumors, and belongs to the field of medicines for treating tumors. The invention particularly relates to a C-Met targeting polypeptide and application thereof in the anti-tumor aspect. The C-Met targeting polypeptide disclosed by the invention has an amino acid sequence of Xa-Gln-Ile-Ile-Ala-Asn-Xb, and can be a pharmaceutically acceptable salt; and the Xa and the Xb are any amino acid deletion or substitution. A large number of experiments show that the c-Met targeting peptide has clear target; and in vivo and in vitro experiments show that the polypeptide with the sequence can effectively inhibit the development of cancers, including but not limited to breast cancer, colon cancer, pancreatic cancer, ovarian cancer, liver cancer, stomach cancer, lung cancer, kidney cancer, brain glioma or melanoma and other human tumors, of which the pathogenesis is mediated by the c-Met. The C-Met targeting polypeptide, designed by the invention, is scientific, reasonable, feasible and effective, and can be used as a therapeutic drug for treating human tumors. Thus, therapeutic spectrum of c-Met targeting drugs are greatly expanded with new ideas and prospects for future drug development provided; and therefore, the has C-Met targeting polypeptide has remarkable social values and market values.

Description

Technical field [0001] The present invention belongs to the field of biopharmaceuticals, and more particularly to a polypeptide having anti-tumor activity and its application thereof. Background technique [0002] With the in-depth of scientific research, the treatment of malignant tumors has entered an individualization and precision targeting era, and the treatment of new targets for the individualization of tumor patients has become the top priority. Hepatocellular growth factor receptor (C-MET) raw carcinolysis Met encoded receptor tyrosine protein kinase, hepatocyte growth factor (HGF) is the only known C-MET natural ligand. A large number of clinical and basic studies have shown that HGF / C-MET signaling pathway plays a vital role in the development of tumors, and has received much attention in the field of anti-tumor treatment in recent years. [0003] At present, the MET receptor activation mechanism has the following four forms: (1) MET gene mutation, such as papillary ...

AI Technical Summary

Problems solved by technology

A total of 48 drugs are under research, including 10 chemical drugs and 2 biological drugs under research. There is no peptide drug targeting this target, and there is no class 1 drug targeting this target in China.

Images